





2

Docket No. 1824A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Osama M. Musa et al.

Serial No.

09/922,187

•

Group Art Unit: 1714

Filed:

08/03/2001

Examiner:

For: CURABLE ELECTRON DONOR COMPOUNDS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. 1.97

Commissioner for Patents Washington, D. C. 20231

SIR:

In compliance with Applicants' duty of disclosure under 37 C.F.R. 1.56, and in accordance with 37 C.F.R. 1.98, Applicants' direct the Examiner's attention to the publications listed on the PTO #1449 form which is being submitted herewith. Copies of all publications listed on the #1449 form are being submitted herewith. It is respectfully submitted that the information should be considered by the Patent Office as it is being filed pursuant to 37 CFR § 1.97(b)(3) before the mailing date of a first office action on the merits or, alternatively pursuant to CFR § 1.97(e)(1), the information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

The disclosure of the above references does not constitute an admission that they are relevant or material to the claims or are "prior art" to the subject application. The citation of them is not to be construed as a representation that no better art exists or that a search has been made; they are cited merely as constituting collectively the closest art of which applicants are aware.

Respectfully subm**i**tted

Jane E Gennaro, Reg. No. 34,884

Attorney for Applicant(s)
Tel 908-685-5205

National Starch and Chemical 10 Finderne Avenue Bridgewater, New Jersey 08807-0500

December 31, 2002

#52237







PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number		
	Application Number	09/922,187
TRANSMITTAL	Filing Date	08/03/2001
FORM	First Named Inventor	Osama M. Musa et al.
1	Group Art Unit	1714
(to be used for all	Examiner Name	
correspondence after initial filing) Total Number of Pages In This Submission:	Attorney Docket Number	1824A
ENCLOSURES (check all that apply)		
☐ Fee Transmittal Form	☐ Assignment Papers	☐ After Allowance Communication
☐ Fee Attached	(for an Application)	to Group
☐ Amendment / Reply	☐ Drawing(s)	☐ Appeal Communication to
☐ After Final	☐ Licensing-related Papers	Board of Appeals and Interferences
☐ Affidavits/declarations(s)	☐ Petition	☐ Appeal Communication to
☐ Extension of Time Request	☐ Petition to Convert to a	Group (Appeal, Notice, Brief, Reply
☐ Express Abandonment Request	Provisional Application	Brief)
☑ Information Disclosure Statement	☐ Power of Attorney, Revocation	☐ Proprietary Information
☐ Certified Copy of Priority Doc(s)	·	☐ Status Letter
☐ Response to Missing	Change of Correspondence	
Parts/Incomplete Application	Address	☐ Other Enclosure(s) (please
Response to Missing Parts	☐ Terminal Disclaimer	identify below):
Under 37 CFR 1.52 or 1.53	☐ Request for Refund	
Olidor 07 Ol 18 1.32 di 1.33	☐ CD, Number of CD(s)	
	Pamarka	
	Remarks	
CIONATU	E OF ADDITIONS ATTORNS	V OD ACENT
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Jane E. Gennaro		
or National Starch and Chemical		
Individual Name		
Signature - Mre Cunaro		
Date - 12/31/02		
CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first		
class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this DATE: 12/3(/b2)		
Typed or Printed Name Anne Marie Pickel A A		
Signature Date /1/3/02		
Burden Hour Statement: This form is estimated to take	0.2 hours to complete. Time will vary depending upon the	needs of the individual case. Any comments on the amoun